Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek C Abraham

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Biomolecular Screening|June 21, 2008
Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humansVivek C Abraham, Danli L Towne, Jeffrey F Waring, et al.
European Journal of Pharmacology|September 14, 2017
Implementation of a human podocyte injury model of chronic kidney disease for profiling of renoprotective compoundsVivek C Abraham, Loan N Miller, Steve D Pratt, et al.
Journal of Biomolecular Screening|June 19, 2012
Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology researchDanli L Towne, Emily E Nicholl, Kenneth M Comess, et al.
Molecular Cancer Research : MCR|November 16, 2018
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone MarrowTodd A Hopkins, William B Ainsworth, Paul A Ellis, et al.
European Journal of Pharmacology|June 12, 2016
A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injuryChang Z Zhu, Sujatha Gopalakrishnan, Kelly Doyle, et al.
Cancer Research|March 10, 2021
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid TumorsDarren C Phillips, Fritz G Buchanan, Dong Cheng, et al.
Molecular Cancer Therapeutics|May 5, 2017
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT InhibitorsJulie L Wilsbacher, Min Cheng, Dong Cheng, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Biomolecular Screening|June 21, 2008
Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humansVivek C Abraham, Danli L Towne, Jeffrey F Waring, et al.
European Journal of Pharmacology|September 14, 2017
Implementation of a human podocyte injury model of chronic kidney disease for profiling of renoprotective compoundsVivek C Abraham, Loan N Miller, Steve D Pratt, et al.
Journal of Biomolecular Screening|June 19, 2012
Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology researchDanli L Towne, Emily E Nicholl, Kenneth M Comess, et al.
Molecular Cancer Research : MCR|November 16, 2018
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone MarrowTodd A Hopkins, William B Ainsworth, Paul A Ellis, et al.
European Journal of Pharmacology|June 12, 2016
A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injuryChang Z Zhu, Sujatha Gopalakrishnan, Kelly Doyle, et al.
Cancer Research|March 10, 2021
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid TumorsDarren C Phillips, Fritz G Buchanan, Dong Cheng, et al.
Molecular Cancer Therapeutics|May 5, 2017
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT InhibitorsJulie L Wilsbacher, Min Cheng, Dong Cheng, et al.
Pageof 1